These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 23681562)

  • 21. Recurrent oligodendroglioma with changed 1p/19q status.
    Barresi V; Mafficini A; Calicchia M; Piredda ML; Musumeci A; Ghimenton C; Scarpa A
    Neuropathology; 2022 Apr; 42(2):160-166. PubMed ID: 35144313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
    Ballester LY; Huse JT; Tang G; Fuller GN
    Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers.
    Minniti G; Arcella A; Scaringi C; Lanzetta G; Di Stefano D; Scarpino S; Pace A; Giangaspero F; Osti MF; Enrici RM
    J Neurooncol; 2014 Jan; 116(2):275-82. PubMed ID: 24162810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation.
    Khurana R; Rath S; Singh HB; Rastogi M; Nanda SS; Chauhan A; Kaif M; Hussain N
    Asian Pac J Cancer Prev; 2020 Mar; 21(3):755-760. PubMed ID: 32212804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.
    McNamara MG; Jiang H; Lim-Fat MJ; Sahebjam S; Kiehl TR; Karamchandani J; Coire C; Chung C; Millar BA; Laperriere N; Mason WP
    Can J Neurol Sci; 2017 May; 44(3):288-294. PubMed ID: 28488951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of
    Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
    AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
    Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
    Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.
    Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS
    Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma.
    Suchorska B; Giese A; Biczok A; Unterrainer M; Weller M; Drexler M; Bartenstein P; Schüller U; Tonn JC; Albert NL
    Neuro Oncol; 2018 Jan; 20(2):279-288. PubMed ID: 29016996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
    Cahill DP; Louis DN; Cairncross JG
    CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution.
    Jiang H; Ren X; Wang J; Zhang Z; Jia W; Lin S
    J Neurooncol; 2014 Jan; 116(2):395-404. PubMed ID: 24264532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
    Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
    Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y
    J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of
    Park YW; Han K; Ahn SS; Choi YS; Chang JH; Kim SH; Kang SG; Kim EH; Lee SK
    AJNR Am J Neuroradiol; 2018 Apr; 39(4):693-698. PubMed ID: 29519794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
    Houillier C; Wang X; Kaloshi G; Mokhtari K; Guillevin R; Laffaire J; Paris S; Boisselier B; Idbaih A; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY
    Neurology; 2010 Oct; 75(17):1560-6. PubMed ID: 20975057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
    Jeon YK; Park K; Park CK; Paek SH; Jung HW; Park SH
    Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
    Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
    Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.